Patents by Inventor John VEKICH

John VEKICH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS

Publication number: 20260193651

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing an oligonucleotide that targets MTRES1 in a subject.

Type: Application

Filed: November 30, 2023

Publication date: July 9, 2026

Inventors: Omri GOTTESMAN, Emma BRANDT, Shannon BRUSE, Paul BUSKE, Eric BUSS, Brian CAJES, David JAKUBOSKY, David LEWIS, Gregory MCINNES, David ROZEMA, John VEKICH, Darren H. WAKEFIELD
TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

Publication number: 20260055410

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.

Type: Application

Filed: March 12, 2025

Publication date: February 26, 2026

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF MS4A4E RELATED DISEASES AND DISORDERS

Publication number: 20250368990

Abstract: Disclosed herein are MS4A4E inhibitors such as oligonucleotides that target MS4A4E. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MS4A4E mutations that include providing an MS4A4E inhibitor to a subject.

Type: Application

Filed: June 15, 2023

Publication date: December 4, 2025

Inventors: Omri GOTTESMAN, Shannon BRUSE, Eric BUSS, Brian CAJES, David JAKUBOSKY, Gregory MCINNES, John VEKICH, David ROZEMA
TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS

Publication number: 20250333732

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.

Type: Application

Filed: May 23, 2023

Publication date: October 30, 2025

Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David JAKUBOSKY, Gregory MCINNES, David ROZEMA, John VEKICH
SMALL MOLECULE TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS

Publication number: 20250327127

Abstract: Disclosed herein are compositions comprising a small molecule that targets MTRES1. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a small molecule that targets MTRES1 in a subject.

Type: Application

Filed: October 23, 2023

Publication date: October 23, 2025

Inventors: Omri GOTTESMAN, Emma BRANDT, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, David LEWIS, Gregory MCINNES, David ROZEMA, John VEKICH
TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

Publication number: 20250313841

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.

Type: Application

Filed: April 3, 2025

Publication date: October 9, 2025

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
Treatment of MST1 related diseases and disorders

Patent number: 12312586

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.

Type: Grant

Filed: August 7, 2024

Date of Patent: May 27, 2025

Assignee: Empirico Inc.

Inventors: Omri Gottesman, Shannon Bruse, Paul Buske, Brian Cajes, David Jakubosky, Sarah Kleinstein, David Lewis, David Rozema, John Vekich
TREATMENT OF FGG RELATED DISEASES AND DISORDERS

Publication number: 20250043281

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.

Type: Application

Filed: December 5, 2022

Publication date: February 6, 2025

Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

Publication number: 20240392295

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MS1. The oligonucleotide may include a small interfering RNA (siRNA) or art antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.

Type: Application

Filed: August 5, 2024

Publication date: November 28, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

Publication number: 20240392296

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.

Type: Application

Filed: August 7, 2024

Publication date: November 28, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF MST1R RELATED DISEASES AND DISORDERS

Publication number: 20240392299

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1R. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1R mutations that include providing an oligonucleotide that targets MST1R to a subject.

Type: Application

Filed: June 14, 2022

Publication date: November 28, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS

Publication number: 20240287518

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing an oligonucleotide that targets MTRES1 in a subject.

Type: Application

Filed: June 14, 2022

Publication date: August 29, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS

Publication number: 20240287517

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets PLIN1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with PLIN1 gene mutations that include providing an oligonucleotide that targets PLIN1 in a subject.

Type: Application

Filed: June 14, 2022

Publication date: August 29, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

Publication number: 20240287523

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.

Type: Application

Filed: April 3, 2024

Publication date: August 29, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS

Publication number: 20240287519

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets DKK2. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of decreasing DKK2 expression by providing an oligonucleotide that targets DKK2 to a subject in need thereof. Some embodiments include methods of treating hair loss by providing the oligonucleotide.

Type: Application

Filed: June 17, 2022

Publication date: August 29, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
MODULATION OF COASY EXPRESSION

Publication number: 20240254492

Abstract: Provided herein are specific inhibitors, compositions, methods and uses for reducing expression of COASY in a cell or individual. Such specific inhibitors, compositions, and methods are useful to treat a liver disease or disorder, including but not limited to NASH, in a subject.

Type: Application

Filed: May 19, 2022

Publication date: August 1, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, John VEKICH, Richard LEE, Susan F. MURRAY
TREATMENT OF MST1 RELATED DISEASES AND DISORDERS

Publication number: 20240175031

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.

Type: Application

Filed: June 14, 2022

Publication date: May 30, 2024

Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS

Publication number: 20230407299

Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.

Type: Application

Filed: November 22, 2021

Publication date: December 21, 2023

Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David JAKUBOSKY, Sarah E. KLEINSTEIN, John VEKICH